Evaluating long-acting HIV treatment in Swiss patients
Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study: Uptake, Outcome, and Risk Factors for Treatment Failures in a Real-world Setting
University of Zurich · NCT06405464
This study is testing how well a long-acting HIV treatment works for Swiss patients starting a new medication regimen to see if it helps them stick to their treatment and improve their health.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Zurich (other) |
| Locations | 1 site (Zurich) |
| Trial ID | NCT06405464 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on participants in the Swiss HIV Cohort Study who are starting the long-acting regimen of Cabotegravir and Rilpivirine. It aims to assess adherence to treatment guidelines and evaluate the outcomes of this regimen across a diverse patient population in Switzerland. The study will also investigate various factors, including virological and immunological responses, that may contribute to treatment failures. By analyzing these elements, the study seeks to enhance understanding of the effectiveness of this treatment approach in real-world settings.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals participating in the Swiss HIV Cohort Study who are initiating the Cabotegravir and Rilpivirine long-acting regimen.
Not a fit: Patients who are not part of the Swiss HIV Cohort Study will not benefit from this research.
Why it matters
Potential benefit: If successful, this study could improve treatment strategies for HIV patients by identifying factors that influence the effectiveness of long-acting therapies.
How similar studies have performed: Other studies have shown promise with long-acting HIV treatments, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participant in the SHCS * All SHCS participants initiating the CAB+RPV LA regimen * All SHCS participants on SOC oral regimen Exclusion Criteria: * Not participating in the SHCS
Where this trial is running
Zurich
- University Hospital Zurich — Zurich, Switzerland (RECRUITING)
Study contacts
- Principal investigator: Jessy J Duran Ramirez, MSc — Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich
- Study coordinator: Dominique L Braun, MD
- Email: dominique.braun@usz.ch
- Phone: 0041442559196
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: HIV Infections